Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Seventh indication approved for Humira

This article was originally published in Scrip

Executive Summary

Abbott's anti-inflammatory Humira (adalimumab), which is set to overtake Lipitor and Plavix to become the world's best-selling drug with sales of around $9 billion expected this year, has now received approval in the EU for its seventh indication, ulcerative colitis, following a CHMP positive opinion earlier this year (scripintelligence.com, 20 February 2012).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register